Evidence: Weak support for the central implication; reasonable grounds for advising nutritional monitoring.

Balance: Gives disproportionate weight to speculative harm relative to established clinical benefits.

Clarity: Readable, but scientifically imprecise about the distinction between weight loss, undernutrition, and brain structural changes.

The article is misleading because it implies that GLP-1 treatment could shrink the brain without direct supporting evidence. The relevant marathon study involved only 10 runners and found temporary changes in an MRI marker of myelin, with no significant reduction in brain volume. It neither tested GLP-1 drugs nor demonstrated cognitive harm. www.nature.com The balance is poor: speculative harm receives disproportionate attention relative to established clinical benefits. Clarity also suffers because calorie restriction, severe undernutrition, and brain atrophy are treated as interchangeable. Nutritional monitoring is appropriate, and medical supervision helps manage risks without eliminating them. A responsible message would emphasise adequate nutrition and follow-up without suggesting that routine GLP-1 treatment causes brain shrinkage.